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Background and Aims: Chronic kidney disease (CKD) is characterized by increased oxidative 2 
stress (OS). In consideration of the well-known link between OS and DNA methylation we assessed 3 
DNA methylcytosine (mCyt) concentrations in CKD patients at baseline and during cholesterol 4 
lowering treatment.  5 
Methods and Results: DNA methylation and OS indices (malonyldialdehyde, MDA; 6 
allantoine/uric acid ratio, All/UA) were measured in 30 CKD patients randomized to three 7 
cholesterol lowering regimens for 12 months (simvastatin 40 mg/day, ezetimibe/simvastatin 10/20 8 
mg/day, or ezetimibe/simvastatin 10/40 mg/day) and 30 age- and sex-matched healthy controls. 9 
DNA methylation was significantly lower in CKD patients vs. controls (4.06±0.20 % vs. 4.27±0.17 10 
% mCyt, p=0.0001). Treatment significantly increased mCyt DNA concentrations in all patients 11 
(4.06±0.04 % at baseline; 4.12±0.03% at 4 months; 4.17± 0.03% at 8 months; and 4.20± 0.02% at 12 
12 months, p=0.0001 for trend). A trend for a greater effect on DNA methylation was observed with 13 
combined treatment ezetimibe/simvastatin 10/40 mg/day (+5.2% after one year treatment). The 14 
treatment-associated mCyt increase was significantly correlated with the concomitant reduction in 15 
MDA concentrations and All/AU ratios.  16 
Conclusion: Our results demonstrate that CKD patients have a lower degree of DNA methylation 17 
and that cholesterol lowering treatment restores mCyt DNA concentrations to levels similar to 18 
healthy controls. The treatment-associated increase in DNA methylation is correlated with a 19 
concomitant reduction in OS markers. 20 
21 



















 There is unequivocal evidence that patients with chronic kidney disease (CKD) develop 2 
accelerated atherosclerosis, with a consequent increase in cardiovascular morbidity and mortality 3 
[1–3].  The main mechanisms underlying the increased cardiovascular disease (CVD) risk in this 4 
population are related to the relatively high preval nce of hypertension, diabetes and obesity [4-5]. 5 
Moreover, patients with CKD often have alterations i  lipoprotein metabolism, which might result 6 
in severe dyslipidemia [6]. Therefore, in view of the cardiovascular risk reduction reached in 7 
hypercholesterolaemic patients, the pharmacological management of hypercholesterolaemia 8 
represents a promising target to reduce CVD risk in CKD patients [7]. Several clinical studies show 9 
that statins, aside from decreasing plasma cholesterol concentrations, may have specific 10 
renoprotective properties and, when combined with renin-angiotensin system (RAS) inhibitors, may 11 
have additional antiproteinuric effects [8]. The combination of statins with ezetimibe (EZE), a 12 
cholesterol absorption inhibitor, exerts additional lipid lowering effects vs statins alone [9]. We 13 
have recently reported that combined simvastatin/ezetimibe therapy reduces inflammatory status 14 
and decreases plasma markers of endothelial dysfunction through a reduction in oxidative stress 15 
(OS) in stage III-IV CKD patients [10-11]. OS occurs when reactive oxygen species (ROS) 16 
production in the body overcomes the intrinsic antioxidant capacity, leading to oxidative attack of 17 
cellular structures such as proteins, lipids and DNA [12]. Furthermore, OS may be associated with 18 
aberrant DNA methylation in some diseases such as cancer and cardiovascular disease [13-14]. OS 19 
is associated with DNA hypomethylation through several mechanism: i) generation of DNA base 20 
adducts, such as 8-hydroxyl-2′-deoxyguanosine (8-OH-dG) and O6-methylguanine, strongly inhibit 21 
methylation of adjacent cytosine residues yielding global DNA hypomethylation [15]; ii) redox 22 
regulation of S-adenosylmethionine (SAM)-dependent me hyltransferases, that have been reported 23 
as potentially redox-sensitive enzymes [16]; iii) downregulation of methionine adenosyltransferase, 24 
which catalyzes the enzymatic addition of methionine to adenosine for the synthesis of SAM, in an 25 















to decreased global DNA methylation through the depletion of SAM in the folate/homocysteine 1 
pathway [18]. Under oxidizing conditions, cystathionine-β-synthase principally direct homocysteine  2 
(Hcy) metabolism through the transsulfuration pathway for the generation of GSH. This, in turn, 3 
reduces the amount of Hcy directed toward the regeneration of methionine, which may result in 4 
decreased SAM concentrations [19]. 5 
 Despite to the well-known presence of OS in CKD and its metabolic link with DNA 6 
methylation, little information is currently available on mCyt concentrations in DNA extracted from 7 
stage III-IV CKD patients [20-21]. Previous studies have either assessed global DNA methylation 8 
patterns in end-stage renal disease (ESRD) [22-23] or focused on site specific DNA methylation 9 
[24-25]. 10 
 Therefore, the aim of our study was to assess a) the concentrations of mCyt in DNA of CKD 11 
patients, and b) whether OS improvement during cholesterol-lowering treatment is associated with a 12 
modification of DNA methylation pattern. Moreover, since hyperhomocysteinaemia, a raised 13 
concentration of the sulphur aminoacid homocysteine in plasma that often occurs in CKD, has been 14 





2.1. Study Population 20 
 Patients recruitment was conducted as previously described [10-11]. In brief, 30 CKD 21 
patients (age 60.2±10.5 years, 19 males) were identified at the Istituto di Patologia Medica - 22 
Azienda Ospedaliero Universitaria, University of Sass ri, with the following inclusion criteria: age 23 
>18 years, plasma LDL-cholesterol concentrations > 100 mg/dL (without concomitant 24 
hypolipidemic drugs), presence of proteinuric CKD defined as creatinine clearance >20 25 
ml/min/1.73 m2 combined with urinary protein excretion rate > 0.3 g/24h, without evidence of 26 















were stage III-IV CKD not receiving dialysis. Exclusion criteria were: previous or concomitant 1 
treatment with steroids, anti-inflammatory and/or immunosuppressive agents, vitamin B6, B12, 2 
folate or statins; evidence or clinical suspicion of obstructive uropathy, type 1 diabetes, vasculitis 3 
and renovascular disease. The latter was ruled out by renal artery echo-Doppler or by following the 4 
American College of Cardiology/American Heart Association guidelines on Peripheral Artery 5 
Disease, that propose that diagnostic testing for renal artery stenosis should be performed in the 6 
presence of one of the following: onset of severe hypertension (blood pressure ≥180 mmHg systolic 7 
and/or 120 mmHg diastolic) after the age of 55 years; unexplained deterioration of kidney function 8 
during antihypertensive therapy, especially an acute and sustained elevation (>50%) in serum 9 
creatinine concentrations within one week of treatment with an angiotensin-converting enzyme 10 
(ACE) inhibitor or angiotensin II receptor blocker (ARB); severe hypertension in patients with 11 
diffuse atherosclerosis, particularly those aged >50 years;  severe hypertension in a patient with an 12 
unexplained atrophic kidney or asymmetry in renal sizes of >1.5 cm; a unilateral small kidney (≤9 13 
cm); severe hypertension in patients with recurrent pisodes of acute pulmonary edema or 14 
refractory heart failure with impaired renal function; a systolic-diastolic abdominal bruit that 15 
lateralizes to one side [26]. 16 
 All patients were on stable treatment with RAS inhibitor therapy (ACE inhibition by 17 
benazepril plus angiotensin II antagonism by valsartan) for at least six months.  Enrolled patients 18 
were randomized to a 12-month treatment with either 40 mg/day simvastatin (group 1, n=10), 19 
ezetimibe/simvastatin 10/20 mg/day (group 2, n=10) or ezetimibe/simvastatin 10/40 mg/day (group 20 
3, n=10). Patients were evaluated at baseline, 4, 8 and 12 months.  21 
 A control group including 30 age- and sex-matched subjects (age 59 ±10 years, 19 males) 22 
was also recruited. Exclusion criteria for control subjects were a history of diabetes, hypertension, 23 
cardiovascular or cerebrovascular disease, renal failure, blood dyscrasias, cancer, retinal vascular 24 















creatinine concentrations in controls were also measured at baseline, 4, 8 and 12 months, to rule out 1 
renal impairment [27]. 2 
 Informed consent was obtained from each subject. The study was approved by the Ethics 3 
Committee of our Institution. The study complied with the principles of the Helsinki Declaration 4 
and was registered at clinicaltrials.gov (NCT00861731). 5 
2.2.Biochemical  analysis 6 
Whole blood DNA methylation was determined as follows. Genomic DNA extraction was 7 
performed by using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to the 8 
instructions supplied by the manufacturer. After extraction DNA was hydrolyzed by 90% formic 9 
acid. Hydrolyzed samples were evaporated and the dry residue containing free bases was dissolved 10 
in ultrapure water and immediately analyzed by capillary electrophoresis as previously described 11 
[28]. The percentage of methylated to total cytosine (mCyt/tCyt) was calculated using the formula: 12 
{[mC] / [mC] + [C]}*100. The inter-assay CV for mCyt/tCyt measurements was 3.3%. 13 
OS indices allantoine/uric acid (All/UA) ratio and malondialdehyde (MDA) were assessed 14 
by capillary electrophoresis UV detection as previously described [29-30]. Plasma Hcy was 15 
measured by laser induced fluorescence (LIF) capillary electrophoresis [31]. 16 
Total plasma cholesterol, LDL, HDL and trygliceride concentrations were assayed by 17 
enzymatic methods using commercial kits (Boehringer-Mannheim, Mannheim, Germany).  18 
eGFR was calculated  by using the CKD-EPI creatinine equation. 19 
2.3.Statistical analysis 20 
 All results are expressed as mean values (mean ± SD) or median values (median and 21 
interquartile range). The variables distribution was ssessed by the Kolmogorov-Smirnov test. 22 
Differences between groups after randomization were t sted by one-way ANOVA or Kruskal-23 
Wallis test as appropriate. Correlation analysis betwe n variables was performed by Pearson's 24 















contribution of different variables to DNA methylation at baseline. The effect of drug treatment was 1 
evaluated by one-way repeated measures ANOVA or Friedman test as appropriate. 2 
 We evaluated that a sample size of 37 patients and 37 controls is needed to ensure a power 3 
of 0.8 to detect a meaningful difference (p<0.05) in DNA methylation levels. 4 
 Statistical analyses were performed using MedCalc for Windows, version 12.5 64 bit 5 
(MedCalc Software, Ostend, Belgium) and SPSS for Windows, version 14.0 32 bit (IBM 6 




 Baseline clinical characteristics of controls and CKD patients are described in Table 1. As 11 
previously reported [10-11], CKD patients showed higher concentrations of plasma triglycerides, 12 
total cholesterol and LDL cholesterol vs. controls. CKD patients also exhibited higher 13 
concentrations of MDA, All/UA ratio and homocystein. As reported in figure 1, CKD patients had 14 
lower mCyt concentrations in DNA extracted from blood when compared with healthy controls 15 
(4.06±0.20% vs. 4.27±0.17%, p=0.0001). At baseline, o significant correlations were observed 16 
between mCyt and OS markers, Hcy or presence of diabetes. Moreover, when serum lipid (LDL, 17 
HDL and triglycerides) concentrations were categorized into tertiles (with tertile I as the lowest and 18 
tertile III as the highest tertile) DNA methylation showed a trend towards a reduction only with 19 
increasing serum LDL concentrations (Figure 2). This was also confirmed by multiple linear 20 
regression analysis that revealed that baseline DNA methylation was negatively correlated only 21 
with LDL cholesterol (β=-0.41, p<0.05) after correction for age, gender, MDA, Hcy and GFR. 22 
 After randomization, no significant differences were found among the three treatment 23 
groups. As previously described [10-11], a significant improvement in lipid profile was observed in 24 
all groups after 4 months of therapy: a mean decrease of 38% in total cholesterol (median 40%, 25 
IQR: 32-44%), 54% in LDL cholesterol (median 56%, IQR: 36-59%), and 15% in triglyceride 26 















(median 2%, IQR:-13-12%). A relatively greater improvement in lipid profile was observed in 1 
group 3: a decrease of 44% in total cholesterol (median 43%, IQR: 40-46%), 65% in LDL 2 
cholesterol (median 64%, IQR: 56-71%), and 21% in triglyceride concentration (median 19%, 3 
IQR:3-47%), and an increase of 6% in HDL concentration (median 8%, IQR:-3-19%). 4 
 Moreover, while a significant decrease in OS parameters (MDA and All/UA ratio) was 5 
observed, indicating a reduction of oxidative stress during drug treatment, Hcy plasma 6 
concentrations remained virtually unchanged [10-11]. 7 
 As reported in Figure 3 drug treatment significantly increased  mCyt content of DNA in all 8 
patients (4.06±0.04% at baseline; 4.12± 0.03% at 4 months; 4.17± 0.03% at 8 months; and 4.20± 9 
0.02% at 12 months) as well as in individual treatment groups: group 1 (4.08±0.07% at baseline; 10 
4.15±0.07% at 4 months; 4.20±0.04% at 8 months; and 4.23±0.03% at 12 months); group 2 11 
(4.07±0.04% at baseline; 4.11±0.04% at 4 months; 4.13±0.05% at 8 months; and 4.16±0.05% at 12 12 
months); group 3 (4.02±0.08% at baseline; 4.10±0.07% at 4 months; 4.16±0.06% at 8 months; and  13 
4.22±0.03% at 12 months). After 12-month treatment, the DNA methylation values in CKD patients 14 
were similar to those of healthy subjects (4.20±0.02% vs 4.27±0.17%, p>0.05).  15 
 Figure 4 describes the ratio between the DNA methyla ion mean values of CKD and control 16 
subjects after one year of therapy in the three treatm nt groups. The greatest effect on DNA 17 
methylation was observed in group 3 (+5.2% after one year treatment), even if the differences with 18 
group 2 and group 1 (+2.3 and +3.6%, respectively) were not statistically significant. 19 
 As shown in figure 5, the increase in mCyt during therapy was significantly correlated to the 20 
reduction in MDA concentrations (r=-0.987, p=0.013) and All/AU ratios (r=-0.983, p=0.017). By 21 
contrast, no associations were observed between the increase in DNA methylation and changes in 22 



















Previous findings suggest a role for DNA methylation in some diseases such as cancer and 2 
cardiovascular disease [13-14]. Moreover, some clinical studies reported altered mCyt 3 
concentrations in DNA of ESRD patients [22-23]. By contrast, relatively little information is 4 
available on DNA methylation patterns in stages III and IV CKD patients [20-21]. In contrast with 5 
previous observations, reporting no differences in DNA methylation between stage III-IV CKD  6 
patients and healthy subjects [20-21], we observed significantly lower concentrations of mCyt in 7 
DNA of CKD patients vs. healthy controls. Discrepancies in the observed findings may be due to 8 
different procedures used to detect DNA methylation. Notably, in our study DNA methylation 9 
values showed a relatively narrow distribution with a particularly low biological variation (inter-10 
individual CV: 4.0% in controls and 4.9% in CKD). It has been previously reported that the 11 
statistical power decreases significantly with increasing measurement imprecision, and this effect is 12 
already apparent with a CV of 3% [32]. This implies that high measurement precision is key to 13 
detect differences between groups. For these reasons, we used a method that ensured an inter-assay 14 
CV of 3.3%, near to values suggested for analytes with a narrow distribution [32]. Previous studies 15 
have reported lower DNA methylation in ESRD patients vs. controls [20, 23]. The similar trend in 16 
patients with mild/moderate CKD mandates the use of high-precision assays to maximise the 17 
chance of detecting statistically significant between-group differences. 18 
 Multiple correlation analysis at baseline showed the presence of inverse associations 19 
between DNA methylation and serum LDL cholesterol concentrations. The latter is in agreement 20 
with previous reports of lower DNA methylation levels in Long Interspersed Nuclear Elements 21 
(LINE-1), a surrogate marker of global methylation analysis, in Samoan Islanders with higher LDL 22 
cholesterol concentrations [33]. Conversely, there was no significant association between DNA 23 
methylation degree and total cholesterol, HDL cholesterol or triglycerides concentrations in CKD 24 
patients. The lower DNA methylation in CKD patients, characterized by a cardiovascular risk that is 25 















healthy men with lower levels of global DNA methylation are more likely to develop cardiovascular 1 
disease [34]. This suggests that DNA methylation might represent a novel marker of cardiovascular 2 
risk, both in CKD and in other patient groups, that is independent of traditional risk factors, 3 
particularly dyslipidaemia. However, it remains to be established whether altered DNA methylation 4 
is a cause or a consequence of cardiovascular disease, and whether treatment-induced changes in 5 
methylation impact on hard end-points such as cardiovascular morbidity and mortality. 6 
 Also in consideration of the relatively high CVD risk, pharmacological interventions to 7 
manage dyslipidaemia in CKD patients have focused on lowering LDL, with statins showing some 8 
beneficial effects in patients with mild-to-moderat CKD (SHARP study) [35]. However, the recent 9 
evidence that CKD patients with low plasma HDL concentrations have a particularly poor 10 
prognosis, is likely to be addressed in future, HDL-targeted, trials in these patients [36].  11 
 Since statins are effective antioxidant agents, we hypothesised that statin therapy could also 12 
induce an increase in DNA methylation levels in CKD patients through improvement in OS 13 
markers. As previously reported [10-11], a significant amelioration in lipid profile was observed in 14 
all groups already after 4 months of therapy, with a relatively greater improvement in group 3. This 15 
was associated with a concomitant reduction in both MDA and All/UA ratios, particularly in group 16 
3 patients. In this study we observed that cholesterol lowering treatment increased DNA mCyt 17 
concentrations in the whole study group (+3.72%), with a relatively greater effect in group 3 18 
(+5.2%). As a result, the level of DNA methylation after 12 months of treatment was similar to that 19 
of healthy people. The increase in DNA methylation levels was associated with a concomitant 20 
reduction in OS markers (MDA and All/AU). This suggests a close relationship between DNA 21 
methylation and OS pathways. A previous study failed to show a significant effect of statin 22 
treatment on DNA mCyt concentrations in CKD [21]. However, the treatment with statin (6 23 
months) was shorter than that in our study (12 months). This might have led to a less prominent 24 
effect on OS when compared with our study. In addition, the statin employed in this study, 25 















possible that the effect magnitude of pravastatin on OS was not sufficient to improve DNA 1 
methylation pattern. 2 
 Ingrosso et al. [23] reported that folate treatment i  ESRD reduces Hcy plasma 3 
concentrations. This would force the homocysteine-methionine cycle through the remethylation 4 
pathway, increasing the intracellular pool of the mthyl donor S-adenosylmethionine and, as a 5 
consequence, DNA methylation. However, in our study homocysteine concentrations did not 6 
change during statin therapy. Furthermore, no associati ns were observed between the increase in 7 
mCyt DNA levels and homocysteine concentrations.  8 
 Our findings of a global DNA methylation alteration in CKD patients vs. controls at baseline 9 
confirm previous observations about site-specific methylation modifications of important target 10 
genes in CKD [25, 38-39]. It has been hypothesized that modifications of DNA methylation pattern 11 
may play an important regulatory role in loss of kidney function through expression or suppression 12 
of key pathway genes [39]. However, the observation of a restoration of the methylation degree 13 
after lipid lowering treatment in our study might pave the way to the identification of novel 14 
treatment strategies and therapeutic targets to prevent the progression of CKD. 15 
 Some limitations of this study deserve mention. As the study was under-powered, our results 16 
require confirmation in larger cohorts. All patients were on stable treatment with RAS inhibitor 17 
therapy (for at least six months) before starting cholesterol lowering therapy. It is currently 18 
unknown whether valsartan and/or benazepril treatment ight affect DNA methylation. The lack of 19 
assessment of the methyl donor SAM does not allow evaluating its impact on baseline mCyt levels, 20 
and their treatment-induced changes. Furthermore, the lack of data about proteinuria in controls, 21 
limits the assessment of the impact of renal functio  on the degree of DNA methylation in this 22 
group. 23 
 In conclusion, our study provides experimental evid nce that CKD patients in stage III and 24 
IV have lower DNA mCyt levels than healthy subjects. A 12-month cholesterol lowering treatment 25 















improvement in DNA methylation was associated with a concomitant reduction in OS indexes. The 1 
potential synergistic effect of the simvastatin/ezetimibe combination vs statin monotherapy warrants 2 
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Figure 1. % of mCyt in DNA extracted from blood in healthy subjects (n=30) and CKD patients 17 
(n=30). The central horizontal line on each box represents the median, the ends of the boxes are the 18 
25 and 75 percentiles, and the error bars indicated th  5% and 95% values. P-values derived from 19 
Student-Newman-Keuls test. 20 
Figure 2. DNA methylation levels according to tertiles of lipid parameters. (A) LDL cholesterol: 21 
tertile I range 104-143 mg/dL; tertile II range 146-173 mg/dL; tertile III range 175-264 mg/dL. (B) 22 
HDL cholesterol:  tertile I range 31-40 mg/dL; tertil  II range 43-51 mg/dL; tertile III range 56-95 23 
mg/dL. (C) Triglycerides: tertile I range 41-116 mg/dL; tertile II range 118-153 mg/dL; tertile III 24 
range 160-296 mg/dL 25 
Figure 3. Effect of drug treatment on DNA methylation in all patients (A) and after categorization 26 
for therapy type: B Group 1 (n = 10), C group 2 (n = 10), D group 3 (n = 10).  p values were 27 
evaluated by one-way repeated measures ANOVA with Bonferroni correction. 28 
Figure 4. Ratio between DNA methylation mean values in CKD and controls after one year of 29 















the ends of the boxes are the 25 and 75 percentiles, and the error bars indicated the 5% and 95% 1 
values. 2 
Figure 5. Trends of DNA methylation and plasma concentrations f oxidative stress indices, in all 3 
patients, during cholesterol lowering treatment. MDA plasma levels vs DNA methylation (A) and 4 













Table 1. Demographic and clinical characteristics of patients and controls 
 Controls 










Number 30 30  
Gender, F 11 11 ns 
Age, Years 59±10 60±11 ns 
BMI 25.2±4.3 27.9±4.4 P<0.05 
Diabetes 3/30 7/30 ns 
Systolic BP, mmHg 124±8 130 ± 9 ns 
Diastolic BP, mmHg 80 (70-90) 80 (60-95) ns 
Creatinine, mg/dL 0.85±0.22 1.75 ± 0.77 P<0.001 
eGFR, ml/min per 1.73 m2 89±17 48 ± 25 P<0.001 
Proteinuria, g/24h -- 0.99 ± 1.27  
Total cholesterol, mg/dL 207±42 239 ± 43 P<0.01 
LDL-C, mg/dL 130±39 160 ± 37 P<0.01 
HDL-C, mg/dL 55±19 49 ±15 ns 












































































































































































Chronic kidney disease is characterized by increased oxidative stress (OS).  
DNA methylation was significantly lower in CKD patients vs. controls.  
Treatment significantly increased mCyt DNA concentrations in CKD patients.  
Methylcytosine rise was significantly correlated with the reduction of OS indices.  
 
